PMID- 16356828
OWN - NLM
STAT- MEDLINE
DCOM- 20060224
LR  - 20131121
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 231
IP  - 1
DP  - 2006 Jan 8
TI  - Modulation of arginine metabolic pathways as the potential anti-tumor mechanism 
      of recombinant arginine deiminase.
PG  - 30-5
AB  - Arginine deiminase (ADI), currently in clinical trials, has various biological 
      activities including anti-proliferation, anti-angiogenesis and inhibition of 
      inducible nitric oxide synthase (iNOS). To recognize limitations and therapeutic 
      applications, the mechanism of ADI modulation of arginine metabolic pathways was 
      investigated. MCF-7 and A549 cells have notable different sensitivity to 
      recombinant ADI (rADI) and express diverse argininosuccinate synthase (AS) 
      activity, which regenerates arginine. Due to compartmentalization of arginine, 
      utilization of arginine for protein synthesis occurs from either the 
      intracellular arginine pool or the citrulline-arginine-regeneration pathway, 
      whereas for polyamine synthesis, utilization is only from the intracellular 
      arginine pool. Modulating AS activity or introducing rADI intracellularly to 
      reduce intracellular arginine regeneration may expand therapeutic applications of 
      rADI.
FAU - Shen, Li-Jiuan
AU  - Shen LJ
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern 
      California, 1985 Zonal Avenue, 404B, Los Angeles, CA 90089-9121, USA.
FAU - Beloussow, Karin
AU  - Beloussow K
FAU - Shen, Wei-Chiang
AU  - Shen WC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Polyamines)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 3.- (Hydrolases)
RN  - EC 3.5.3.6 (arginine deiminase)
SB  - IM
MH  - Adenocarcinoma/pathology
MH  - Arginine/*metabolism
MH  - Breast Neoplasms/pathology
MH  - Humans
MH  - Hydrolases/*pharmacology
MH  - Lung Neoplasms/pathology
MH  - Neoplasms/drug therapy
MH  - Nitric Oxide
MH  - Nitric Oxide Synthase/metabolism
MH  - Polyamines
MH  - Protein Biosynthesis/*drug effects
MH  - Tumor Cells, Cultured
EDAT- 2005/12/17 09:00
MHDA- 2006/02/25 09:00
CRDT- 2005/12/17 09:00
PHST- 2004/08/13 00:00 [received]
PHST- 2004/12/02 00:00 [revised]
PHST- 2005/01/07 00:00 [accepted]
PHST- 2005/12/17 09:00 [pubmed]
PHST- 2006/02/25 09:00 [medline]
PHST- 2005/12/17 09:00 [entrez]
AID - S0304-3835(05)00040-6 [pii]
AID - 10.1016/j.canlet.2005.01.007 [doi]
PST - ppublish
SO  - Cancer Lett. 2006 Jan 8;231(1):30-5. doi: 10.1016/j.canlet.2005.01.007.